Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28342244 | 0.85 | ALDH1A1 (0.53) | TSHRALDH1A1NAPRTTDP1KDM4E | |
| Pyridine SCHEMBL30127 | 0.85 | ALDH1A1 (0.53) | TSHRALDH1A1NAPRTTDP1KDM4E | |
| Benzene SCHEMBL3700434 | 0.85 | ALDH1A1 (0.53) | TSHRALDH1A1NAPRTTDP1KDM4E | |
| Pyridine SCHEMBL3755683 | 0.85 | ALDH1A1 (0.53) | TSHRALDH1A1NAPRTTDP1KDM4E | |
| Pyridine SCHEMBL7939106 | 0.85 | ALDH1A1 (0.53) | TSHRALDH1A1NAPRTTDP1KDM4E | |
| Pyridine SCHEMBL2017900 | 0.83 | TSHR (0.50) | TSHRHTTNAPRTTDP1KDM4E | |
| Pyridine SCHEMBL11554309 | 0.83 | TSHR (0.50) | TSHRHTTNAPRTTDP1KDM4E | |
| Pyridine SCHEMBL27529683 | 0.81 | ALDH1A1 (0.48) | TSHRALDH1A1NAPRTTDP1KMT2A | |
| Pyridine SCHEMBL27296235 | 0.81 | TSHR (0.47) | TSHRHTTNAPRTTDP1KDM4E | |
| Pyridine SCHEMBL28099571 | 0.81 | TSHR (0.47) | TSHRHTTNAPRTTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170087205-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | PALATIN TECHNOLOGIES INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20160354443-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | PALATIN TECHNOLOGIES INC (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2015175502-A2 | REPLACEMENT THERAPY FOR NATRIURETIC PEPTIDE DEFICIENCIES | PALATIN TECHNOLOGIES, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| US-8828926-B2 | Uses of natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8580747-B2 | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580746-B2 | Amide linkage cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130274207-A9 | Uses of Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| EP-2001518-B1 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2560670-A2 | USES OF NATRIURETIC PEPTIDE CONSTRUCTS | Palatin Technologies, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130045928-A1 | Uses of Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| EP-2004633-A2 | LINEAR NATRIURETIC PEPTIDE CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-2004352-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-2001518-A2 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007115164-A9 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070265206-A1 | Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007115175-A2 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115164-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115182-A2 | LINEAR NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265206-A1 | Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | TSHR 44/4885ALDH1A1 4870/4885HTT 2912/4885 |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | ARGLU1, ARG1, QRFPR | TSHR 250/4885ALDH1A1 2657/4885HTT 1880/4885 |
| US-20130045928-A1 | Uses of Natriuretic Peptide Constructs | NPR1, NPPA, NPR3 | TSHR 227/4885ALDH1A1 4693/4885HTT 3493/4885 |
| US-20170087205-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | NPR1, NPR3, NPPA | TSHR 102/4885ALDH1A1 4847/4885HTT 1740/4885 |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | TSHR 40/4885ALDH1A1 4786/4885HTT 2750/4885 |
| US-20130274207-A9 | Uses of Natriuretic Peptide Constructs | NPR1, NPPA, NPR3 | TSHR 227/4885ALDH1A1 4693/4885HTT 3493/4885 |
| US-20160354443-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | NPR1, NPR3, NPPA | TSHR 102/4885ALDH1A1 4847/4885HTT 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.